Companies
ALSOLIFE
its digital therapy intervention for childhood autism spectrum disorder has entered 14 hospitals and 3 rehabilitation institutions in Hainan province, achieving a 94% effective intervention rate under a Hainan government subsidy program (approximately 3,000 yuan per patient),…
- Country
- China
Government-subsidized
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | 11.1112 million RMB registered capital | qiye.qizhidao.com |
| Headcount | 0 (as of 2025) | qiye.qizhidao.com |
| Headcount | over 400 rehabilitation therapists (making up about 4/5 of total staff) | m.36kr.com |
| Production site | 14 offline rehabilitation centers in cities including Beijing, Tianjin, Xi'an, and Zhengzhou | m.36kr.com · vcbeathealth.com |
| Regulatory approval | acquired China's first Class II medical device certificate in the field of autism | m.36kr.com · m.tech.china.com · asd-home.cn · vcbeathealth.com |
| Certification | ISO9001, ISO14001, ISO45001, information security management, and five-star after-sales service certifications | alsolife.com |
| Certification | certified digital therapy assistant therapists (China Pharmaceutical Education Association) | alsolife.com |
Independent sources: asd-home.cn · m.36kr.com · m.tech.china.com · qiye.qizhidao.com · vcbeathealth.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Digital therapeutics | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.